Breast cancer in northern Peru: molecular subtypes and HER2 low




Breast Neoplasms, inmunohistochemistry, receptor ErbB-2, biomarkers tumor


This study aimed to understand the immunohistochemical profile of breast cancer and to identify the HER2 low subgroup in the northern macro-region of Peru. A cross-sectional study was conducted in
1176 patients from the Regional Institute of Neoplastic Diseases Northern Peru, from January 2016 to December 2023. We analyzed the data (age, histological type, grade and complementary results), with frequencies and percentages. The profile corresponded to: luminal B (45.6%); luminal A (24.7%); triple negative (18.2%); and HER2 positive non luminal (11.5%). In addition, 215 patients presented HER2 low (25.1% of those previously considered negative). This study provides evidence that the subtyping of breast cancer has changed, being luminal B the most frequent. It is essential to involve health policies to acquire targeted therapies considering HER2 low patients.


Download data is not yet available.


American Cancer Society. [citado 8 de febrero de 2023]. Cancer facts & figures 2022. Disponible en:

World Health Organization. Peru Source: Globocan 2020 [Internet]. International agency for research on cancer. 2021 [citado 13 de marzo de 2023]. Disponible en:

Clasificación de la OMS de tumores, tumores de mama. 5ª edición. Ginebra, Suiza: Organización Mundial de la Salud, Agencia Internacional para la Investigación del Cáncer; 2019.

Zhang X. Molecular Classification of Breast Cancer: Relevance and Challenges. Arch Pathol Lab Med [Internet]. 1 de enero de

;147(1):46-51. doi: 10.5858/arpa.2022-0070-RA.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature.

;406(6797):747-752. doi: 10.1038/35021093.

Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, et al. 13th st. Gallen international breast cancer conference 2013:

primary therapy of early breast cancer evidence, controversies, consensus opinion of a german team of experts (zurich 2013). Breast Care (Basel). 2013;8(3):221-229. doi: 10.1159/000351692.

Vallejos C, Gómez H, Cruz W, Pinto J, Dyer R, Velarde R, et al. Breast cancer classification according to immunohistochemistry markers:

subtypes and association with clinicopathologic variables in a peruvian hospital database. Clinical breast cancer. 2010;10(4):294–300. doi: 10.3816/CBC.2010.n.038.

Medina G. Características clínicas y pronósticas de los subtipos moleculares de cáncer de mama determinados por inmunohistoquímica. Arequipa, Perú. Rev Peru Med Exp Salud Publica. 2017;34(3):472-7. doi: 10.17843/rpmesp.2017.343.2530.

Chachaima-Mar J, Pineda-Reyes J, Marin R, Lozano-Miranda Z, Chian-García C. Perfil inmunofenotípico de cáncer de mama de

pacientes atendidas en un hospital general de Lima, Perú. Rev Med Hered. 2020; 31(4): 235-241. doi: 10.20453/rmh.v31i4.3855.

Zavala VA, Casavilca-Zambrano S, Navarro-Vásquez J, Tamayo LI, Castañeda CA, Valencia G, et al. Breast cancer subtype and clinical

characteristics in women from Peru. Front Oncol. 2023;13:938042. doi: 10.3389/fonc.2023.938042.

Sajjadi E, Guerini-Rocco E, De Camilli E, Pala O, Mazzarol G, Venetis K, et al. Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test. Frontiers in Molecular Biosciences. 2023;10. doi: 10.3389/fmolb.2023.1176309.

Molinelli C, Jacobs F, Marchiò C, Pitto F, Cosso M, Spinaci S, et al. HER2-Low Breast Cancer: Where Are We?. Breast Care (Basel).

;17(6):533-545. doi: 10.1159/000527391.

Office of the Commissioner. U.S. Food and Drug Administration. FDA; 2022 [citado 1 de agosto de 2023]. FDA Approves First Targeted

Therapy for HER2-Low Breast Cancer. Disponible en:

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing

in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Arch Pathol Lab Med 2018;142. doi: 10.5858/arpa.2018-0902-SA.

Ramírez-Torres N, Reyes-López A, Hernández-Valencia M. Asociando factores pronósticos con resultados clínicos en cáncer de mama

localmente avanzado [Associating prognostic factors with clinical results in locally advanced breast cancer]. Rev Med Inst Mex Seguro

Soc. 2023;61(1):88-98. PMID: 36542781.

Setyawati Y, Rahmawati Y, Widodo I, Ghozali A, Purnomosari D. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman. Asian Pac J Cancer Prev. 2018;19(5):1263-1268. doi:10.22034/


Firdaus VR, Asri A, Khambri D, Harahap WA. Hubungan grading histopatologi dan infiltrasi limfovaskular dengan subtipe molekuler

pada kanker payudara invasif di Bagian Bedah RSUP. JKMA. 2016;5(1):165–72. doi: 10.25077/jka.v5i1.463.

Creighton CJ. The molecular profile of luminal B breast cancer. Biologics. 2012; 6: 289-297. doi: 10.2147/BTT.S29923.

Susman S, Berindan-Neagoe I, Petrushev B, Pirlog R, Florian IS, Mihu CM, et al. The role of the pathology department in the preanalytical phase of molecular analyses. Cancer Manag Res. 2018; 10: 745-753. doi: 10.2147/CMAR.S150851.

Corti C, Giugliano F, Nicolò E, Tarantino P, Criscitiello C, Curigliano G. HER2-Low Breast Cancer: a New Subtype? Curr Treat Options

Oncol. 2023;24(5):468-478. doi: 10.1007/s11864-023-01068-1.

Zhang H, Peng Y. Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer. Cancers (Basel). 2022;15(1):126.

doi: 10.3390/cancers15010126.

Da Silva JL, Carvalho GDS, Zanetti de Albuquerque L, Rodrigues FR, Fernandes PV, Kischinhevsky D, et al. Exploring Real-World HER2-

Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications. Breast Cancer (Dove Med Press). 2023;15:337-347. doi:






Brief Report

How to Cite

Gómez-Rázuri K, Abad-Licham M, Astigueta J, Moreno J. Breast cancer in northern Peru: molecular subtypes and HER2 low. Rev Peru Med Exp Salud Publica [Internet]. 2024 Mar. 25 [cited 2024 Apr. 23];41(1):62-8. Available from: